Adaptive Dietary Intervention (ADI) for Asian Americans With Type 2 Diabetes
Key facts
- Where
- New York, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who are first- or second-generation Chinese or Vietnamese immigrants, to test a diet plan guided by a glucose sensor.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with Hb1Ac above 7.0%.
- Earlier treatment
- People who currently use or used a continuous glucose monitor (Dexcom or FreeStyle Libre) and plan to keep using it in the next 6 months cannot join. People taking insulin or sulfonylureas cannot join.
- Biomarker or test result
- Hb1Ac above 7.0%.
Main reasons for not taking part
- Taking insulin, sulfonylureas or similar medicines that can cause low blood sugar
- Pregnant, breastfeeding, or planning pregnancy in the next 6 months
- Serious physical illness or mental illness, such as stroke, COPD or schizophrenia
- Cancer treatment, or marked kidney impairment (eGRF<45)
- Taking part in another type 2 diabetes study
Read by machine on 9 November 2026.
Where in United States
- NYU Langone HealthNew York, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NYU Langone Health
- Trial code
- NCT07278531
- Record updated
- 13 August 2026
- Original description
The investigators will examine the feasibility, acceptability, and effect of an adaptive dietary intervention over 24 weeks (12-week intervention, 12-week follow-up) among Asian Americans with Type 2 diabetes. Participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans) will be 2:1 randomized to one of two arms: adaptive dietary intervention or standard of care (SC). The intervention will begin with continued glucose monitoring (CGM) use only during weeks 0-4. At week 4, participants who achieve the glycemic control goal (at least an 8% increase in time in range [TIR] from baseline) will continue with the CGM alone during weeks 4-12 ("CGM Alone"); otherwise, culturally and linguistically adapted glucose excursion minimization (GEM) will be augmented with CGM ("CGM-GEM").Read full original descriptionShow less
Adaptive Dietary Intervention (ADI) Leveraging Continuous Glucose Monitoring for Asian Americans With Type 2 Diabetes
The investigators will examine the feasibility, acceptability, and effect of an adaptive dietary intervention over 24 weeks (12-week intervention, 12-week follow-up) among Asian Americans with Type 2 diabetes. Participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans) will be 2:1 randomized to one of two arms: adaptive dietary intervention or standard of care (SC). The intervention will begin with continued glucose monitoring (CGM) use only during weeks 0-4. At week 4, participants who achieve the glycemic control goal (at least an 8% increase in time in range [TIR] from baseline) will continue with the CGM alone during weeks 4-12 ("CGM Alone"); otherwise, culturally and linguistically adapted glucose excursion minimization (GEM) will be augmented with CGM ("CGM-GEM").
Inclusion: Eligible participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans); Community-dwelling adults aged ≥ 18 with independent living; Diagnosed with T2D; Hb1Ac>7.0%; Self-identified as first- or second-generation Chinese or Vietnamese immigrants; Able to communicate in English, Chinese, or Vietnamese. We will focus on Mandarin-, Cantonese- or English-speaking Chinese Americans because the two best-known and most-spoken variants of Chinese are Mandarin and Cantonese, who use the same writing system; Have a smartphone, iPad, tablet, or Apple watch.
Exclusion: Taking hypoglycemia agents (e.g., insulin and sulfonylureas) with the major side effect of hypoglycemia that need close monitoring the occurrence of hypoglycemia to adjust/reduce medications to avoid future hypoglycemia; Taking medications that impede weight loss (e.g., prednisone) within the last 3 months; Are prior or current CGM users including both Dexcom and FreeStyle Libre and plan to continuously use these CGMs in the next 6 months; Have serious physical complications (e.g., severe neuropathy cardiovascular disease, COPD/emphysema, osteoarthritis, or stroke) or mental disease (e.g., schizophrenia, bipolar disorder, manic depressive illness, severe depression, or active substance abuse); Have conditions that restrict diet, such as severe gastroparesis, ulcers, or food allergies. These conditions may need special dietary intervention; Undergoing treatment for cancer, as cancer treatment may impact the outcome of glucose changes; Have marked renal impairment (eGRF<45; CKD-3b), as renal impairment may needs special dietary intervention and they also may impact glucose changes; Are taking psychotropic medications that raise blood glucose (e.g., atypical antipsychotics); Currently pregnant, breastfeeding, or contemplating pregnancy within the next 6 months; Are participating in another T2D intervention study.